StockNews.AI
ADVM
StockNews.AI
116 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM

1. Pomerantz LLP investigates potential securities fraud against Adverum Biotechnologies. 2. Adverum will restate financial statements due to identified accounting errors. 3. Stock price dropped 12.36% to $3.83 on the news of restatement. 4. Investors are encouraged to contact Pomerantz for potential claims. 5. Historical precedent indicates significant risks due to securities investigations.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The investigation and subsequent stock drop reveal severe financial trust issues. Companies facing similar past investigations, like Enron, saw drastically negative impacts on stock prices and investor confidence.

How important is it?

The severity of the investigation and its implications on financial integrity are crucial for ADVM's valuation. Misstatements and fraud allegations typically scare off investors and further diminish stock value.

Why Short Term?

Investors typically react swiftly to allegations of fraud and restatements. Historical events suggest immediate sell-offs and price drops following such disclosures, likely impacting ADVM in the coming weeks.

Related Companies

ENRNAMRNVYGR
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Adverum Biotechnologies, Inc. (“Adverum” or the “Company”) (NASDAQ: ADVM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Adverum and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 31, 2025, Adverum disclosed in a filing with the U.S. Securities and Exchange Commission that “certain of the Company’s previously issued financial statements should no longer be relied upon due to non-cash errors identified in the accounting for tenant improvement allowances associated with an operating lease and sublease related to a building in North Carolina (the ‘NC Premises’).” Accordingly, Adverum announced that it will restate its “financial statements as of and for the years ended December 31, 2022 and 2023, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 . . . , as well as the unaudited condensed consolidated quarterly financial information for the quarterly periods in the years ended December 31, 2023 and 2024.” On this news, Adverum’s stock price fell $0.54 per share, or 12.36% to close at $3.83 per share on April 1, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News